Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Buy
64
VRDN Quote, Financials, Valuation and Earnings
Last price:
$33.03
Seasonality move
:
-1.98%
Day range:
$32.72 - $34.04
52-week range:
$9.90 - $34.04
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
37.88x
P/B ratio:
10.04x
Volume:
2.5M
Avg. volume:
1.8M
1-year change:
85.04%
Market cap:
$3.2B
Revenue:
$302K
EPS (TTM):
-$3.53
Analysts' Opinion
-
Consensus RatingViridian Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $40.13, Viridian Therapeutics, Inc. has an estimated upside of 21.48% from its current price of $33.03.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $26.00 representing 21.28% downside risk from its current price of $33.03.
Fair Value
-
According to the consensus of 14 analysts, Viridian Therapeutics, Inc. has 21.48% upside to fair value with a price target of $40.13 per share.
VRDN vs. S&P 500
-
Over the past 5 trading days, Viridian Therapeutics, Inc. has overperformed the S&P 500 by 4.67% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Viridian Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Viridian Therapeutics, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Viridian Therapeutics, Inc. reported revenues of $70.6M.
Earnings Growth
-
Viridian Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Viridian Therapeutics, Inc. reported earnings per share of -$0.42.
Enterprise value:
2.9B
EV / Invested capital:
5.46x
Price / LTM sales:
37.88x
EV / EBIT:
--
EV / Revenue:
40.60x
PEG ratio (5yr expected):
-15.90x
EV / Free cash flow:
-8.81x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$69.7M
Return On Assets:
-43.02%
Net Income Margin (TTM):
-405.28%
Return On Equity:
-47.79%
Return On Invested Capital:
-46.01%
Operating Margin:
-56.7%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $347K | $302K | $70.8M | $86K | $70.6M | |
| Gross Profit | -$730K | -$1.3M | $69.7M | -$244K | $70.3M | |
| Operating Income | -$232M | -$283M | -$328.1M | -$83.5M | -$40M | |
| EBITDA | -$230.9M | -$281.5M | -$327.1M | -$83.2M | -$39.7M | |
| Diluted EPS | -$5.11 | -$4.31 | -$3.53 | -$1.15 | -$0.42 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $217.9M | $431.3M | $323.8M | $767.4M | $571.9M | |
| Total Assets | $221.2M | $440.6M | $328.8M | $771.9M | $577.1M | |
| Current Liabilities | $14.3M | -- | $23.2M | $41.4M | $50.7M | |
| Total Liabilities | $16.6M | -- | $45.2M | $64.4M | $74.2M | |
| Total Equity | $204.6M | $409M | $283.6M | $707.5M | $503M | |
| Total Debt | $2.3M | -- | $21.2M | $22.7M | $23.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$197M | -$326M | -$67.7M | -$84.6M | |
| Cash From Investing | -- | -$335.4M | $238.9M | -$84.7M | $126.1M | |
| Cash From Financing | -- | $621.2M | $56.4M | $245M | $10.9M | |
| Free Cash Flow | -- | -$197.4M | -$326.3M | -$68M | -$84.7M | |
VRDN
Sector
Market Cap
$3.2B
$28M
Price % of 52-Week High
97.03%
51.86%
Dividend Yield
0%
0%
Shareholder Yield
-3.19%
-1.4%
1-Year Price Total Return
85.04%
-19%
Beta (5-Year)
0.914
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$32.33
200-day SMA
Buy
Level
$18.61
Bollinger Bands (100)
Buy
Level
17.66 - 27.88
Chaikin Money Flow
Buy
Level
1.1M
20-day SMA
Buy
Level
$31.25
Relative Strength Index (RSI14)
Buy
Level
70.10
ADX Line
Buy
Level
43.61
Williams %R
Neutral
Level
-26.4398
50-day SMA
Buy
Level
$26.81
MACD (12, 26)
Buy
Level
4.91
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
15.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12.6758)
Sell
CA Score
(Annual)
Level (-0.8008)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (4.8602)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (5)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
Stock Forecast FAQ
In the current month, VRDN has received 13 Buy ratings 1 Hold ratings, and 0 Sell ratings. The VRDN average analyst price target in the past 3 months is $40.13.
-
Where Will Viridian Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Viridian Therapeutics, Inc. share price will rise to $40.13 per share over the next 12 months.
-
What Do Analysts Say About Viridian Therapeutics, Inc.?
Analysts are divided on their view about Viridian Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Viridian Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $26.00.
-
What Is Viridian Therapeutics, Inc.'s Price Target?
The price target for Viridian Therapeutics, Inc. over the next 1-year time period is forecast to be $40.13 according to 14 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is VRDN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Viridian Therapeutics, Inc. is a Buy. 13 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VRDN?
You can purchase shares of Viridian Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Viridian Therapeutics, Inc. shares.
-
What Is The Viridian Therapeutics, Inc. Share Price Today?
Viridian Therapeutics, Inc. was last trading at $33.03 per share. This represents the most recent stock quote for Viridian Therapeutics, Inc.. Yesterday, Viridian Therapeutics, Inc. closed at $33.03 per share.
-
How To Buy Viridian Therapeutics, Inc. Stock Online?
In order to purchase Viridian Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get VRDN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
VRDN
Sector
P/E ratio
--
24.31x
PEG ratio
-15.90x
-0.01x
P/B ratio
10.04x
1.83x
Price / LTM sales
37.88x
1.60x
Growth Metrics
VRDN
Sector
Revenue growth
81958.14%
4.6%
Earnings growth
63.36%
10.88%
Revenue (5-year growth)
-41.64%
6.5%
Earnings forecast
-$0.94
-$0.20
Profitability
VRDN
Sector
Profitability FY 2024
-$938K
$3.5M
Return on invested capital
-46.01%
-31.66%
Return on assets
-43.02%
-27.84%
Return on equity
-47.79%
-37.28%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
4
Balance Sheet
VRDN
Sector
Total cash
$490.9M
$26.8M
Short term investments
$618M
$26M
Total assets
$742.4M
$78.7M
Long term debt
$23.1M
$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
71
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
39
SMX alert for Dec 16
SMX (Security Matters) Plc [SMX] is down 20.63% over the past day.
Sell
33
ZBIO alert for Dec 16
Zenas BioPharma, Inc. [ZBIO] is up 5.95% over the past day.
Sell
38
HUT alert for Dec 16
Hut 8 Corp. [HUT] is down 3.47% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
